Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New test set to target growth hormone misuse:

This article was originally published in Clinica

Executive Summary

Researchers have developed an immunoassay that could indicate whether an athlete has misused recombinant human growth hormone (r-hGH). "Doping" has until now been considered undetectable because once injected, r-hGH is identical to a form of naturally occurring pituitary-derived human growth hormone, said the research team, which was led by Dr Christian Strasburger of Innenstadt University Hospital, Munich, Germany. In an assessment of 165 serum samples, the test correctly ruled out everyone who had not used r-hGH, according to a letter published in The Lancet (March 13).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel